Ligand binding site of rage and uses thereof

Details Ligand binding site of rage and uses thereof Ligand binding site of rage and uses thereof

A - Human Necessities

61

K

A61K 38/00 (2006.01) C07K 5/00 (2006.01)

Patent

CA 2306991

The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation end product (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L- V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (Seq. ID No. 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid-.beta. peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid-.beta. peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid-.beta. peptide with the receptor for advanced glycation end product.

Peptide isolé ayant une séquence d'acides aminés correspondant à la séquence d'acides aminés d'un domaine V d'un récepteur de produit terminal de glycation avancée (RAGE). La présente invention concerne également un peptide isolé ayant une séquence d'acides aminés A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (Séq. ID No 1). Elle concerne encore une composition pharmaceutique comportant une quantité thérapeutiquement efficace d'un peptide isolé ayant une séquence d'acides aminés correspondant à la séquence d'acides aminés du domaine V de RAGE. Elle concerne enfin un procédé permettant d'inhiber l'interaction d'un peptide amyloïde .beta. avec un récepteur de produit terminal de glycation avancée qui est sur la surface d'une cellule. Ledit procédé consiste à mettre en contact la cellule avec le peptide ou un agent fonctionnellement équivalent, ledit peptide ou agent étant capable d'inhiber l'interaction du peptide amyloïde .beta. avec le récepteur de produit terminal de glycation avancée, et étant présent en quantité efficace pour provoquer ladite inhibition.

Affiliated with

Also associated with

Rating

Ligand binding site of rage and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ligand binding site of rage and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligand binding site of rage and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2067292